FROM:
Alternative Medicine Review 1998 (Jun); 3 (3): 227–229 ~ FULL TEXT
Description and Constituents
Serenoa repens (also known as Sabal
serrulata, Saw Palmetto or Dwarf palm) is native to the United States South
Atlantic coast and Florida, as well as Southern Europe and North Africa.
This small palm tree grows to a height of six to ten feet, and has a fan-shaped
crown of leaves and dark red berries approximately the size of olives (See Figure 1).
Traditional indications for the
use of Saw palmetto include: cystitis, chronic bronchitis, asthma, diabetes,
dysentery, indigestion, and for "underdeveloped breasts." The
berries have also been thought to be an aphrodisiac.1 Modern usage of Saw
palmetto is overwhelmingly for the treatment of benign prostatic hyperplasia
(BPH).
The berries contain approximately
1.5 percent volatile oil, of which 63 percent are free fatty acids and
38 percent are ethyl esters of those fatty acids. The fatty acids include:
caproic, caprylic, capric, lauric, palmitic, and oleic acids, and ethyl
esters of these. In addition, the berries contain beta-sitosterol and its
glucoside, beta sitosterol D-glucoside, as well as ferulic acid. [1]
Clinical Uses and Mechanisms
of Action
The liposterolic extract of the
fruit, standardized to contain at least 85 percent fatty acids and sterols,
is currently used in the treatment of BPH.
Benign prostatic hyperplasia is
one of the most common medical conditions in middle-aged and elderly males,
with an incidence of approximately 50-60 percent in men age 40-60, and
greater than 90 percent in men over 80. The disease process leading to
symptomatology in older males probably begins as early as the late 20s,
and may have an incidence rate of 10 percent at that age. Rarely a fatal
disease, BPH affects the patients' lifestyle and comfort. [2]
A non-malignant hypertrophy of the
prostate which is caused by hormonal processes and/or imbalances within
the prostate, BPH begins in the periurethral region and includes the stromal,
epithelial, and smooth muscle tissues of the gland. The fibrous capsule
surrounding the gland forces most of the growth inward, compressing the
urethra and causing the typical urinary symptoms characteristic of the
disease, including: decreased force and caliber of the urine stream, urinary
hesitancy, urgency, frequency, post-void dribbling, incomplete emptying
of the bladder, dysuria, and nocturia. [2]
Testosterone is converted in prostatic
cells to dihydrotestosterone (DHT), catalyzed by the enzyme steroid 5-alpha-reductase
(5-AR). DHT binds to androgen receptors in the nucleus of prostate cells,
stimulating cellular growth and division. [3-5]
In BPH tissue, 5-AR levels are higher than in tissue not affected by BPH. [4,5]
The presence of DHT may also stimulate 5-AR activity, causing a positive
feedback loop, and more DHT.6 The standardized liposterolic Serenoa extract
has been found to be a potent inhibitor of 5-AR, resulting in decreased
tissue DHT. Serenoa also competitively inhibits binding of testosterone
and DHT to cytosolic and nuclear androgen receptors. [7-9]
Another component of BPH is inflammation
within the prostate gland. A standardized Serenoa extract has been shown
to inhibit 5-lipoxygenase and thus the downstream pro-inflammatory arachidonic
acid metabolites leukotriene B4 (LTB4) and 5-hydroxyeicosatetraenoic acid
(5-HETE). [10]